Bio­gen CEO Vounatsos, board and top ex­ecs for­mal­ly agreed to keep the breakup civ­il

If the pleas­antries ex­changed to­day be­tween the Bio­gen board and CEO Michel Vounatsos looked a bit in­tri­cate­ly script­ed to you, even by cor­po­rate PR stan­dards, their 10Q filed with the SEC of­fers a pos­si­ble glimpse as to why.

It ex­plains just how metic­u­lous they’ve been to avoid any un­pleas­antries dur­ing his long good­bye as the com­pa­ny hunts a suc­ces­sor.

Ac­cord­ing to a let­ter filed with the 10Q, the two par­ties came to an agree­ment re­gard­ing the stock Vounatsos gets next Feb­ru­ary dur­ing their vest­ing date. Much of the stock will be giv­en on a pro-rat­ed ba­sis now, based on how much time he ful­filled by the time he leaves — rather than lose the shares due to his de­par­ture ahead of the vest­ing date.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER